Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Exclusion Criteria

• •Are there suspected metastases or locally advanced, unresectable disease, regardless of disease stage.
• •Is currently participating in a study of an investigational agent or using an investigational device.
• •Has undergone major surgery within 30 days of Study Day 1.
• •Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
• •Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \[qualitative\] is detected).
• •History of myocardial infarction, unstable angina, congestive heart failure within 12 months prior to day 1 of study treatment.
• •Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
• •Has received a live virus vaccine within 30 days of the planned first dose of study therapy.